Monoclonal antibodies (or mAbs) are a critical tool in fighting the COVID-19 pandemic, and the U.S. Department of Health and Human Services (HHS) is committed to fair and equitable access to these important products. A surge in the Delta variant coupled with low vaccination rates in certain areas of the country contributed to an increase in COVID-19 over the July-August timeframe.
As a result, the HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) implemented a State and Territorial-Coordinated Distribution System for mAbs on Sep 13, 2021, similar to one that was in place from November 2020 to February 2021. Currently,
REGEN-COV and
bamlanivimab/etesevimab are being distributed through this state/territory coordinated distribution system.
|
Questions?
If you have questions about the new state/territory coordinated distribution system, check out our frequently asked questions section.
View the FAQs >> |